URGN

Over the past six months, UroGen Pharma Ltd. (URGN) experienced a 102.76% stock price increase between September 30, 2025, and September 29, 2026. As of September 24, 2026, the stock was trading below its 50-day moving average but significantly above its 200-day moving average, though it fell by 12.8% on October 9, 2026. Key company events included reporting Q2 2026 financial results with surging revenue due to ZUSDURI adoption on August 5, 2026. On August 17, 2026, UroGen submitted a New Drug Application (NDA) for UGN-103, and on August 20, 2026, it announced strategic collaboration and investment agreements with IntraGel. The company announced presentations at upcoming investor conferences on September 2, 2026, and inducement grants under Nasdaq Listing Rule 5635(c)(4) on September 4, 2026. UroGen received a new U.S. patent allowance for ZUSDURI and UGN-103 on July 15, 2026, expected to provide protection into July 2044. UroGen Pharma is scheduled to report its Q3 2026 earnings on November 5, 2026, with historical data indicating that URGN shares have moved higher in the immediate aftermath of earnings reports in 8 out of 12 previous instances, with an average increase of 2.0% on the first trading day.